The MemoSorb® Fully Absorbable Occluder was Successfully Implanted for the first Time in China.

The MemoSorb® fully absorbable occluder was successfully implanted after the listing in Fuwai Hospital of the Chinese Academy of Medical Sciences and Fuwai Huazhong Cardiovascular Hospital, marking the start of official clinical application of the MemoSorb® fully degradable occluder system. Memosorb will then provide more advanced and rich treatment options for congenital heart disease patients in China and around the world, and the interventional treatment of congenital heart disease has entered a new era of "intervention without implantation".

On July 26, Professor Pan Xiangbin of Fuwai Hospital, Chinese Academy of Medical Sciences, implanted a MemoSorb fully absorbable occluder in a 3-year-old child with congenital heart disease in Beijing. The same day, Professor Fan Taibing from Fuwai Huazhong Cardiovascular Hospital in Zhengzhou implanted MemoSorb fully absorbable occluder for a 3-year-old and a 2-year-old child with congenital heart disease. The treatment of ventricular septal defect was successfully completed in 3 children. Post-ultrasound showed that the occluder was well formed, with no residual shunt, and the treatment effect was ideal.

（Preoperative oesophagal ultrasound）

（Postoperative oesophagal ultrasound）

Ventricular septal defect is common congenital heart disease, accounting for about 30%-50% of the total number of congenital heart diseases. At present, interventional occlusion is one of the standard methods for treating ventricular septal defect. The traditional metal occluder used in operation will remain permanently in the patient's body, which may cause related long-term complications. In addition, most patients with congenital heart disease are infants and young children. Hence, the heart continues to grow and develop as they grow, and the myocardial tissue will gradually thicken. The fixed size of the metal occluder implanted in the human body brings long-term risks, such as heart block.

To solve the above problems, Lepu Medical's subsidiary, ScienTech cooperated with the National Cardiovascular Disease Center, the Fuwai Hospital of the Chinese Academy of Medical Sciences, and the National Biomedical Materials Engineering Technology Research Center of Sichuan University. It took 9 years to develop a fully absorbable occluder system with China's independent intellectual property rights, breaking through another technical barrier in interventional therapy devices for congenital heart disease. The device is made of medical polymer materials. After completing the repair function of the heart defect, it gradually degrades into water and carbon dioxide and is safely absorbed by human tissues. The absorption cycle is designed based on the human tissue repair cycle. The occluder is like a bridge to help the autologous tissue climb and repair. After the occlusion is completed in the first 6 months, it is absorbed gradually. After one year, the "intervention without implantation" is realized, allowing children with congenital heart disease to regain a healthy heart and grow up healthy like a normal child. In the future, Lepu Medical's subsidiary, ScienTech will continue to adhere to the mission of "care from the heart," take absorbable technology and absorbable device products as a new starting point, closely meet clinical needs, and continue to innovate to benefit more patients, letting more Chinese original technologies benefit China and the world!

Surgery video